PAM
CNCE

Paradigm Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Paradigm Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-6,850
Closed -$69.2K – 882
2014
Q2 		$69.2K Buy
+6,850
New +$66.2K 0.01% 677

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Paradigm Asset Management's CNCE Position: Q3 2014 in Review

Paradigm Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2014, closing a stake of 6,850 shares — an estimated $69.2K sold.

Paradigm Asset Management first reported a position in CNCE in Q2 2014 and held it in 1 quarter. The position peaked at $69.2K in Q2 2014. 51 funds tracked by Wall St. Rank hold CNCE as of Q3 2014.

  • Paradigm Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Paradigm Asset Management sold 6,850 Concert Pharmaceuticals, Inc. shares in Q3 2014, an estimated $69.2K.
  • Paradigm Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Paradigm Asset Management's Concert Pharmaceuticals, Inc. position peaked at $69.2K in Q2 2014.
  • 51 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2014.

Based on Paradigm Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.